Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Determination of Beta-cell Responsiveness to the Incretin Hormones GLP-1 and GIP in Cystic Fibrosis
Brief Summary: In recent years, diabetes has emerged as one of the most significant co-diseases that many Cystic Fibrosis (CF) patients develop. Type 1 (T1D) and Type 2 (T2D) diabetes results when either the body does not make enough insulin or the body does not respond correctly to this insulin, respectively. Insulin is a hormone which is made by cells in the pancreas and helps carry glucose (sugar) from the food we eat to the cells of the body for energy. While cystic fibrosis related diabetes (CFRD) has many features similar to both T1D and T2D, patients with CF may not have the same symptoms as either T1D or T2D patients. Currently, there is little understanding of CFRD and the best options for treatment remain unclear.

The purpose of this research study is to examine and understand the various mechanisms that contribute to CFRD and gain a better understanding of potential means to treat CFRD. In particular, we plan to study the effects of incretin hormones that can enhance insulin production in CF patients.

Enrollment is complete for the protocol as initially written. In order to further study the role of the incretin hormone on Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) function , we have received approval to extend our investigation to include the following study groups:

* Cystic Fibrosis participants with normal glucose tolerance
* Non-Cystic Fibrosis controls


Options:
A: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])
B: Arm Label: Burlulipase; Type: EXPERIMENTAL; Interventions: Drug: Burlulipase | Arm Label: Placebo (Caramel in sterile water); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (Caramel in sterile water) | Intervention Type: DRUG; Name: Burlulipase; Assigned to Arm(s): Burlulipase | Intervention Type: DRUG; Name: Placebo (Caramel in sterile water); Assigned to Arm(s): Placebo (Caramel in sterile water)
C: Arm Label: EUR-1008 (APT-1008) First, Then Placebo; Type: EXPERIMENTAL; Interventions: Drug: EUR-1008 (APT-1008), Drug: Placebo | Arm Label: Placebo First, Then EUR-1008 (APT-1008); Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: EUR-1008 (APT-1008) | Intervention Type: DRUG; Name: EUR-1008 (APT-1008); Assigned to Arm(s): EUR-1008 (APT-1008) First, Then Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): EUR-1008 (APT-1008) First, Then Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo First, Then EUR-1008 (APT-1008) | Intervention Type: DRUG; Name: EUR-1008 (APT-1008); Assigned to Arm(s): Placebo First, Then EUR-1008 (APT-1008)
D: Arm Label: GLP-1 Incretin Hormone; Type: EXPERIMENTAL; Interventions: Drug: GLP-1 | Arm Label: GIP Incretin Hormone; Type: EXPERIMENTAL; Interventions: Drug: GIP | Intervention Type: DRUG; Name: GLP-1; Assigned to Arm(s): GLP-1 Incretin Hormone | Intervention Type: DRUG; Name: GIP; Assigned to Arm(s): GIP Incretin Hormone

Answer: D